vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Dine Brands Global, Inc. (DIN). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $217.6M, roughly 1.1× Dine Brands Global, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -5.6%, a 16.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 6.3%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-8.6M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 2.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Dine Brands Global Inc. is a publicly traded food and beverage company based in Pasadena, California. Founded in 1958 as IHOP, it operates franchised and corporate owned full-service restaurants including three restaurant concepts, Applebee's Neighborhood Grill & Bar, International House of Pancakes (IHOP), and Fuzzy's Taco Shop.
ANIP vs DIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $217.6M |
| Net Profit | $27.5M | $-12.2M |
| Gross Margin | — | 42.4% |
| Operating Margin | 14.1% | -7.6% |
| Net Margin | 11.1% | -5.6% |
| Revenue YoY | 29.6% | 6.3% |
| Net Profit YoY | 367.5% | -336.1% |
| EPS (diluted) | $1.14 | $-0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $217.6M | ||
| Q3 25 | $227.8M | $216.2M | ||
| Q2 25 | $211.4M | $230.8M | ||
| Q1 25 | $197.1M | $214.8M | ||
| Q4 24 | $190.6M | $204.8M | ||
| Q3 24 | $148.3M | $195.0M | ||
| Q2 24 | $138.0M | $206.3M | ||
| Q1 24 | $137.4M | $206.2M |
| Q4 25 | $27.5M | $-12.2M | ||
| Q3 25 | $26.6M | $7.3M | ||
| Q2 25 | $8.5M | $13.8M | ||
| Q1 25 | $15.7M | $8.2M | ||
| Q4 24 | $-10.3M | $5.2M | ||
| Q3 24 | $-24.2M | $19.1M | ||
| Q2 24 | $-2.3M | $23.2M | ||
| Q1 24 | $18.2M | $17.5M |
| Q4 25 | — | 42.4% | ||
| Q3 25 | — | 39.1% | ||
| Q2 25 | — | 40.0% | ||
| Q1 25 | — | 42.0% | ||
| Q4 24 | — | 41.7% | ||
| Q3 24 | — | 47.8% | ||
| Q2 24 | — | 48.1% | ||
| Q1 24 | — | 47.2% |
| Q4 25 | 14.1% | -7.6% | ||
| Q3 25 | 15.9% | 4.7% | ||
| Q2 25 | 6.6% | 8.2% | ||
| Q1 25 | 13.3% | 6.0% | ||
| Q4 24 | -2.3% | 3.8% | ||
| Q3 24 | -13.8% | 13.6% | ||
| Q2 24 | 3.7% | 15.1% | ||
| Q1 24 | 14.8% | 11.7% |
| Q4 25 | 11.1% | -5.6% | ||
| Q3 25 | 11.7% | 3.4% | ||
| Q2 25 | 4.0% | 6.0% | ||
| Q1 25 | 8.0% | 3.8% | ||
| Q4 24 | -5.4% | 2.5% | ||
| Q3 24 | -16.3% | 9.8% | ||
| Q2 24 | -1.7% | 11.2% | ||
| Q1 24 | 13.2% | 8.5% |
| Q4 25 | $1.14 | $-0.79 | ||
| Q3 25 | $1.13 | $0.48 | ||
| Q2 25 | $0.36 | $0.89 | ||
| Q1 25 | $0.69 | $0.53 | ||
| Q4 24 | $-0.45 | $0.35 | ||
| Q3 24 | $-1.27 | $1.24 | ||
| Q2 24 | $-0.14 | $1.50 | ||
| Q1 24 | $0.82 | $1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $128.2M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $540.7M | $-273.9M |
| Total Assets | $1.4B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $128.2M | ||
| Q3 25 | $262.6M | $167.9M | ||
| Q2 25 | $217.8M | $194.2M | ||
| Q1 25 | $149.8M | $186.5M | ||
| Q4 24 | $144.9M | $186.7M | ||
| Q3 24 | $145.0M | $169.6M | ||
| Q2 24 | $240.1M | $153.5M | ||
| Q1 24 | $228.6M | $145.0M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $540.7M | $-273.9M | ||
| Q3 25 | $505.8M | $-231.9M | ||
| Q2 25 | $436.8M | $-212.5M | ||
| Q1 25 | $418.6M | $-215.7M | ||
| Q4 24 | $403.7M | $-216.0M | ||
| Q3 24 | $405.9M | $-216.7M | ||
| Q2 24 | $455.8M | $-231.7M | ||
| Q1 24 | $452.0M | $-244.8M |
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $1.3B | $1.8B | ||
| Q1 25 | $1.3B | $1.8B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $920.8M | $1.7B | ||
| Q1 24 | $914.5M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $5.7M |
| Free Cash FlowOCF − Capex | $29.1M | $-8.6M |
| FCF MarginFCF / Revenue | 11.8% | -3.9% |
| Capex IntensityCapex / Revenue | 0.5% | 6.6% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $53.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $5.7M | ||
| Q3 25 | $44.1M | $30.2M | ||
| Q2 25 | $75.8M | $37.0M | ||
| Q1 25 | $35.0M | $16.1M | ||
| Q4 24 | $15.9M | $30.5M | ||
| Q3 24 | $12.5M | $25.5M | ||
| Q2 24 | $17.4M | $21.6M | ||
| Q1 24 | $18.3M | $30.6M |
| Q4 25 | $29.1M | $-8.6M | ||
| Q3 25 | $38.0M | $18.1M | ||
| Q2 25 | $71.8M | $31.0M | ||
| Q1 25 | $32.5M | $12.8M | ||
| Q4 24 | $13.5M | $26.7M | ||
| Q3 24 | $7.7M | $22.0M | ||
| Q2 24 | $13.0M | $18.2M | ||
| Q1 24 | $13.7M | $27.2M |
| Q4 25 | 11.8% | -3.9% | ||
| Q3 25 | 16.7% | 8.4% | ||
| Q2 25 | 34.0% | 13.4% | ||
| Q1 25 | 16.5% | 6.0% | ||
| Q4 24 | 7.1% | 13.0% | ||
| Q3 24 | 5.2% | 11.3% | ||
| Q2 24 | 9.4% | 8.8% | ||
| Q1 24 | 10.0% | 13.2% |
| Q4 25 | 0.5% | 6.6% | ||
| Q3 25 | 2.7% | 5.6% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 1.3% | 1.9% | ||
| Q3 24 | 3.2% | 1.8% | ||
| Q2 24 | 3.2% | 1.7% | ||
| Q1 24 | 3.3% | 1.6% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 4.12× | ||
| Q2 25 | 8.87× | 2.68× | ||
| Q1 25 | 2.23× | 1.97× | ||
| Q4 24 | — | 5.88× | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | 1.00× | 1.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
DIN
| Franchisor | $163.2M | 75% |
| Food And Beverage | $27.3M | 13% |
| Proprietary Product Sales And Other | $17.0M | 8% |
| Other | $8.1M | 4% |
| Franchise And Development Fees | $2.0M | 1% |
